TIL cell therapy for melanoma that spread to the liver
Treatments studied
Part of Cancer, Eyes & vision, Skin clinical trials.
This Phase 1 trial tests a treatment using a patient’s own immune cells (TILs) plus a brief period of chemotherapy to help the immune system fight melanoma that has spread mainly to the liver. It may be an option if your melanoma has progressed after prior medicines and you have liver lesions that can be removed to make the cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be able to sign consent and follow all study steps
- Have stage IV uveal melanoma, or stage IV skin (cutaneous) melanoma that has progressed after prior systemic treatment (including a PD-1 medicine, and possibly CTLA-4 and BRAF/MEK medicines if you have a BRAF mutation)
- Your scans must show measurable melanoma in the liver (with liver being the main place the cancer has spread)
- You must have at least one liver lesion that can be surgically removed (about 0.5 cm or larger) to grow the TIL cells
- Be well enough to participate (ECOG health/activity score 0 to 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if immune cells taken from a liver tumor can be given back to fight metastatic melanoma. It is for people with stage IV uveal or cutaneous melanoma that has worsened after standard treatments.
This trial tests using your own immune cells (TILs) to fight advanced uveal melanoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, or angiosarcoma. It aims to see if this treatment can shrink tumors or slow their growth.
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
This trial tests a new T-cell therapy made from your own tumor (TILs), genetically edited to remove the PD1 checkpoint blocker. It may help your immune system fight melanoma that has not responded to standard treatments like anti-PD1 therapy.
This trial tests a personalized cell therapy using your own immune cells (TILs) grown in a lab. It is for people with advanced melanoma that did not respond to or stopped responding to prior immunotherapy.
This trial tests a new treatment called tumor infiltrating lymphocyte (TIL) therapy for melanoma that hasn't responded to standard immunotherapy drugs. The therapy involves taking immune cells from your tumor, growing more of them in the lab, and putting them back into your body to fight the cancer.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.